Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan. The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge’s approval, would not resolve claims against Mylan, which is scheduled to face trial in January. Paul Geller, a lawyer for the plaintiffs, said they were “pleased that Pfizer resolved its part of this class-action lawsuit over the pricing of EpiPens.” Pfizer, which did not admit wrongdoing, did not immediately respond to a request for comment. The EpiPen is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine. The litigation followed a public outcry in 2016 after Mylan, which owns the rights to market …